Key facts
- This page summarizes Joel R. Jung's Form 4 filing for Renalytix plc (RNLXY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2024, 16:15.
Joel R. Jung - 11 Jun 2024 Form 4 Insider Report for Renalytix plc (RNLXY)
- Reporting relationship
- Interim Chief Financial Office
- Issuer ticker
- RNLXY
- Reported as of
- 11 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2024, 16:15:05 UTC
- Prior SEC filing
- 05 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katie Kazem, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joel R. Jung filed Form 4 for Renalytix plc (RNLXY) on 13 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNLX
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 11 Jun 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 60,000
- Exercise price
- $0.2067
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The exercise price is 0.1625 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.2067 using the Bank of England rate as of June 10, 2024 (1.00 pound sterling = $1.272).
Footnote F2
One fourth (1/4th) of the shares subject to the option award shall vest on August 28, 2024, and the remaining shares shall vest in nine equal monthly installments thereafter, subject to the Reporting Person's continuous service.